Transgenic Mice with −6A Haplotype of the Human Angiotensinogen Gene Have Increased Blood Pressure Compared with −6G Haplotype*

Hypertension is a serious risk factor for cardiovascular disease, and the angiotensinogen (AGT) gene locus is associated with human essential hypertension. The human AGT (hAGT) gene has an A/G polymorphism at −6, and the −6A allele is associated with increased blood pressure. However, transgenic mice containing 1.2 kb of the promoter with −6A of the hAGT gene show neither increased plasma AGT level nor increased blood pressure compared with −6G. We have found that the hAGT gene has three additional SNPs (A/G at −1670, C/G at −1562, and T/G at −1561). Variants −1670A, −1562C, and −1561T almost always occur with −6A, and variants −1670G, −1562G, and −1561G almost always occur with −6G. Therefore, the hAGT gene may be subdivided into either −6A or −6G haplotypes. We show that these polymorphisms affect the binding of HNF-1α and glucocorticoid receptor to the promoter, and a reporter construct containing a 1.8-kb hAGT gene promoter with −6A haplotype has 4-fold increased glucocorticoid-induced promoter activity as compared with −6G haplotype. In order to understand the physiological significance of these haplotypes in an in vivo situation, we have generated double transgenic mice containing either the −6A or −6G haplotype of the hAGT gene and the human renin gene. Our ChIP assay shows that HNF-1α and glucocorticoid receptor have stronger affinity for the chromatin obtained from the liver of transgenic mice containing −6A haplotype. Our studies also show that transgenic mice containing −6A haplotype have increased plasma AGT level and increased blood pressure as compared with −6G haplotype. Our studies explain the molecular mechanism involved in association of the −6A allele of the hAGT gene with hypertension.

[1]  Andrew D. Johnson,et al.  Genome-wide association study of blood pressure and hypertension , 2009, Nature Genetics.

[2]  T. Stobdan,et al.  Significance of angiotensinogen gene haplotypes and genotypes combinations in hypertension , 2008, Journal of hypertension.

[3]  Ashok Kumar,et al.  HNF-1alpha plays an important role in IL-6-induced expression of the human angiotensinogen gene. , 2007, American journal of physiology. Cell physiology.

[4]  Simon C. Potter,et al.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.

[5]  J. Hokanson,et al.  Polymorphisms of the Renin-Angiotensin System Genes Predict Progression of Subclinical Coronary Atherosclerosis , 2007, Diabetes.

[6]  C. Sigmund,et al.  Genetic basis of hypertension: revisiting angiotensinogen. , 2006, Hypertension.

[7]  A. Chakravarti,et al.  A Population Association Study of Angiotensinogen Polymorphisms and Haplotypes With Left Ventricular Phenotypes , 2005, Hypertension.

[8]  H. Cohen,et al.  Glucocorticoids Regulate Transcription of the Gene for Phosphoenolpyruvate Carboxykinase in the Liver via an Extended Glucocorticoid Regulatory Unit* , 2005, Journal of Biological Chemistry.

[9]  Nancy A. Jenkins,et al.  Simple and highly efficient BAC recombineering using galK selection , 2005, Nucleic acids research.

[10]  Ashok Kumar,et al.  A single-nucleotide polymorphism in human angiotensinogen gene is associated with essential hypertension and affects glucocorticoid induced promoter activity , 2005, Journal of Molecular Medicine.

[11]  Richard W. Hanson,et al.  Factors That Control the Tissue-Specific Transcription of the Gene for Phosphoenolpyruvate Carboxykinase-C , 2005, Critical reviews in biochemistry and molecular biology.

[12]  C. V. van Duijn,et al.  Angiotensinogen Promoter B-Haplotype Associated With Cerebral Small Vessel Disease Enhances Basal Transcriptional Activity , 2004, Stroke.

[13]  C. Zoccali,et al.  Genetic polymorphism of the renin–angiotensin–aldosterone system and arterial hypertension in the Italian population: the GENIPER Project , 2003, Journal of hypertension.

[14]  B. Nordestgaard,et al.  Angiotensinogen Gene Polymorphism, Plasma Angiotensinogen, and Risk of Hypertension and Ischemic Heart Disease: A Meta-Analysis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[15]  D. Davis,et al.  Physiological significance of two common haplotypes of human angiotensinogen using gene targeting in the mouse. , 2002, Physiological genomics.

[16]  I. Gabriely,et al.  Differential Gene Expression Between Visceral and Subcutaneous Fat Depots , 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[17]  D. Ramji,et al.  CCAAT/enhancer-binding proteins: structure, function and regulation. , 2002, The Biochemical journal.

[18]  J. Flier,et al.  A Transgenic Model of Visceral Obesity and the Metabolic Syndrome , 2001, Science.

[19]  M. Torres-Padilla,et al.  An enhancer element 6 kb upstream of the mouse HNF4alpha1 promoter is activated by glucocorticoids and liver-enriched transcription factors. , 2001, Nucleic acids research.

[20]  M. Stoffel,et al.  Hepatocyte nuclear factor-1α is an essential regulator of bile acid and plasma cholesterol metabolism , 2001, Nature Genetics.

[21]  R. Davisson,et al.  Long-term telemetric measurement of cardiovascular parameters in awake mice: a physiological genomics tool. , 2001, Physiological genomics.

[22]  F. Fazekas,et al.  Angiotensinogen Gene Promoter Haplotype and Microangiopathy-Related Cerebral Damage: Results of the Austrian Stroke Prevention Study , 2001, Stroke.

[23]  D. Davis,et al.  Highly Regulated Cell Type-restricted Expression of Human Renin in Mice Containing 140- or 160-Kilobase Pair P1 Phage Artificial Chromosome Transgenes* , 1999, The Journal of Biological Chemistry.

[24]  O. MacDougald,et al.  The Role of C/EBP Genes in Adipocyte Differentiation* , 1998, The Journal of Biological Chemistry.

[25]  A. Kumar,et al.  DBP binds to the proximal promoter and regulates liver-specific expression of the human angiotensinogen gene. , 1998, Biochemical and biophysical research communications.

[26]  D. Webb,et al.  Increased glucocorticoid activity in men with cardiovascular risk factors. , 1998, Hypertension.

[27]  S. Hunt,et al.  Increased urinary free cortisol: a potential intermediate phenotype of essential hypertension. , 1998, Hypertension.

[28]  C. Darimont,et al.  Regulation by glucocorticoids of angiotensinogen gene expression and secretion in adipose cells. , 1997, The Biochemical journal.

[29]  H. Nechushtan,et al.  Involvement of HNF‐1 in the regulation of phosphoenolpyruvate carboxykinase gene expression in the kidney , 1997, FEBS letters.

[30]  John Quackenbush,et al.  A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. , 1997, The Journal of clinical investigation.

[31]  M. Takiguchi,et al.  The Glucocorticoid-responsive Gene Cascade , 1997, The Journal of Biological Chemistry.

[32]  M. Takiguchi,et al.  Induction of the C/EBP beta gene by dexamethasone and glucagon in primary-cultured rat hepatocytes. , 1996, Journal of biochemistry.

[33]  R. Pictet,et al.  Glucocorticoids and protein kinase A coordinately modulate transcription factor recruitment at a glucocorticoid-responsive unit , 1995, Molecular and cellular biology.

[34]  N. Iwai,et al.  Angiotensinogen gene and blood pressure in the Japanese population. , 1995, Hypertension.

[35]  H. S. Kim,et al.  Genetic control of blood pressure and the angiotensinogen locus. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Fukamizu,et al.  Angiotensinogen-deficient mice with hypotension. , 1994, The Journal of biological chemistry.

[37]  O. MacDougald,et al.  Glucocorticoids reciprocally regulate expression of the CCAAT/enhancer-binding protein alpha and delta genes in 3T3-L1 adipocytes and white adipose tissue. , 1994, The Journal of biological chemistry.

[38]  R. Hammer,et al.  Cell‐specific expression of cytosolic phosphoenolpyruvate carboxykinase in transgenic mice , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  Steven C. Hunt,et al.  Molecular basis of human hypertension: Role of angiotensinogen , 1992, Cell.

[40]  H. Baumann,et al.  Role of CAAT-enhancer binding protein isoforms in the cytokine regulation of acute-phase plasma protein genes. , 1992, The Journal of biological chemistry.

[41]  K. Fuxe,et al.  High blood pressure in transgenic mice carrying the rat angiotensinogen gene. , 1992, The EMBO journal.

[42]  D. Ron,et al.  Synergistic enhansons located within an acute phase responsive enhancer modulate glucocorticoid induction of angiotensinogen gene transcription. , 1990, Molecular endocrinology.

[43]  D. Ron,et al.  Multiple cis-acting DNA regulatory elements mediate hepatic angiotensinogen gene expression. , 1989, Molecular endocrinology.

[44]  J. Habener,et al.  Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. , 1986, The Journal of clinical investigation.

[45]  R. Roeder,et al.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. , 1983, Nucleic acids research.

[46]  K. Mossman The Wellcome Trust Case Control Consortium, U.K. , 2008 .

[47]  A. Gould,et al.  Kinetics of the human renin and human substrate reaction. , 1971, Cardiovascular research.